Hepatol Commun March 2023 PMID 36757421

Safety and tolerability of obeticholic acid in chronic liver disease: a pooled analysis of 1878 individuals.

Cheng Han Ng, Ansel Shao Pin Tang, Jieling Xiao, Zhen Yu Wong, Jie Ning Yong, Clarissa E Fu, Rebecca W Zeng, Caitlyn Tan, Gabriel Hong Zhe Wong, Margaret Teng, Douglas Chee, Darren Jun Hao Tan, Kai En Chan, Daniel Q Huang, Nicholas W S Chew

Download social card

Mentions

Peak: 2 in Feb 2023

across 2 sources since Feb 2023

Extended reach

228

potential audience

Total likes

Video views

Mentions per month

Feb 2023 – Jun 2023

Where it's discussed

X / Twitter2 posts
YouTube1 videos

AI synopsis

What people are saying

Several discussions highlight the significance of the pooled analysis, such as calls to 'access the article' and comments about its relevance to current treatments, reflecting both curiosity and cautious optimism. The tone combines enthusiasm for new research with acknowledgment of safety issues, indicating balanced engagement and potential influence on medical practice.

AgreementModerate agreement

Most discussions acknowledge the findings, with some emphasizing the potential of OCA despite safety concerns.

InterestHigh interest

Participants show high interest, with many eager to access the research and discuss its implications.

EngagementModerate engagement

Responses tend to include some commentary on the methodology or safety profile, indicating moderate engagement.

ImpactModerate impact

The discussions suggest that the publication could influence future research or clinical considerations, but the overall impact remains cautious.

Abstract in brief

Obeticholic acid (OCA) is being studied for its effectiveness in treating both primary biliary cholangitis (PBC) and non-alcoholic steatohepatitis (NASH), showing beneficial results in reducing liver fibrosis.
A systematic review of randomized controlled trials involving 1,878 patients indicated a significant increase in certain side effects such as pruritus (itchiness), constipation, and hyperlipidemia (high cholesterol).
While the safety profile shows concerns regarding tolerability due to these adverse events, OCA is still a potential first pharmacological treatment for NASH, necessitating further long-term safety studies.

Read the full abstract

All mentions